Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial
Durvalumab联合奥拉帕尼和紫杉醇治疗高危HER2阴性II/III期乳腺癌:来自适应性随机I-SPY2试验的结果
期刊:Cancer Cell
影响因子:44.5
doi:10.1016/j.ccell.2021.05.009
Pusztai, Lajos; Yau, Christina; Wolf, Denise M; Han, Hyo S; Du, Lili; Wallace, Anne M; String-Reasor, Erica; Boughey, Judy C; Chien, A Jo; Elias, Anthony D; Beckwith, Heather; Nanda, Rita; Albain, Kathy S; Clark, Amy S; Kemmer, Kathleen; Kalinsky, Kevin; Isaacs, Claudine; Thomas, Alexandra; Shatsky, Rebecca; Helsten, Theresa L; Forero-Torres, Andres; Liu, Minetta C; Brown-Swigart, Lamorna; Petricoin, Emmanuel F; Wulfkuhle, Julia D; Asare, Smita M; Wilson, Amy; Singhrao, Ruby; Sit, Laura; Hirst, Gillian L; Berry, Scott; Sanil, Ashish; Asare, Adam L; Matthews, Jeffrey B; Perlmutter, Jane; Melisko, Michelle; Rugo, Hope S; Schwab, Richard B; Symmans, W Fraser; Yee, Doug; Van't Veer, Laura J; Hylton, Nola M; DeMichele, Angela M; Berry, Donald A; Esserman, Laura J